Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast cancer. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer's Sutent, in combination with Bristol-Myers Squibb's Taxol, has advantages in this attribute over sales-leading Roche/Chugai's Avastin and Taxol.
The new report entitled Metastatic Triple-Negative Breast Cancer: Physicians Want More-Efficacious Therapies for This Niche CaB Population finds that a therapy that improves progression-free survival for patients would earn a 65 percent patient share in metastatic triple-negative breast cancer in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European oncologists.
In 2008, Decision Resources' proprietary clinical gold standard for metastatic triple-negative breast cancer was the combination of Avastin and Taxol. Based on available data and expert opinion, the combination of Sutent and Taxol will earn gold-standard status for metastatic triple-negative breast cancer in 2012, following Sutent's approval for the indication in 2010 in the U.S. and Europe.
"Physicians anticipate that the combination of Sutent and Taxol will be more effective than currently available therapies in improving progression-free survival," said Decision Resources Analyst Niamh Murphy, Ph.D. "Interviewed thought leaders indicate that Sutent has shown compelling preclinical data and they are encouraged by clinical trial results of Sutent monotherapy."
About the Report
Metastatic Triple-Negative Breast Cancer: Physicians Want More-Efficacious Therapies for This Niche CaB Population is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
email@example.com, or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/